Maria JosÃ© Pm SÃ¡

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7576036/publications.pdf

Version: 2024-02-01

67 papers	2,156 citations	331538 21 h-index	233338 45 g-index
74 all docs	74 docs citations	74 times ranked	3478 citing authors

#	Article	IF	Citations
1	Pediatric neuromyelitis optica spectrum disorders in Portugal: A multicentre retrospective study. Multiple Sclerosis and Related Disorders, 2022, 59, 103531.	0.9	2
2	Pregnancy in multiple sclerosis: A reflection on the importance of individualizing management. Clinical and Experimental Neuroimmunology, 2021, 12, 171-174.	0.5	1
3	Infectious Risk Mitigation in Patients with Multiple Sclerosis under Disease-Modifying Therapies â€“ the Experience of a Collaborative Neurology-Infectious Diseases Approach. Journal of Central Nervous System Disease, 2021, 13, 117957352110421.	0.7	3
4	Assessment of cognitive functions in patients with multiple sclerosis applying the normative values of the Raoâ€™s brief repeatable battery in the Portuguese population. BMC Neurology, 2021, 21, 170.	0.8	4
5	RISCOPâ€“Cognitive profile in a Portuguese cohort of radiological isolated syndrome patients: A case-control study. Multiple Sclerosis and Related Disorders, 2021, 50, 102832.	0.9	0
6	TyPed study: Natalizumab for the treatment of pediatric-onset multiple sclerosis in Portugal. Multiple Sclerosis and Related Disorders, 2021, 51, 102865.	0.9	9
7	Defining the prodromal phase of multiple sclerosis based on healthcare access in a Portuguese Population - ProdMS Study. Multiple Sclerosis and Related Disorders, 2021, 55, 103154.	0.9	1
8	Natural history of relapsing remitting multiple sclerosis in a long-lasting cohort from a tertiary MS centre in Portugal. Multiple Sclerosis and Related Disorders, 2021, 54, 103091.	0.9	2
9	Therapeutic inertia in relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 55, 103176.	0.9	4
10	State of the Art and Future Challenges in Multiple Sclerosis Research and Medical Management: An Insight into the 5th International Porto Congress of Multiple Sclerosis. Neurology and Therapy, 2020, 9, 281-300.	1.4	3
11	Trends in hospital readmissions in Multiple Sclerosis patients between 2009 and 2015. Multiple Sclerosis and Related Disorders, 2020, 45, 102396.	0.9	2
12	The epidemiology of multiple sclerosis in the entre Douro e Vouga region of northern Portugal: a multisource population-based study. BMC Neurology, 2020, 20, 195.	0.8	10
13	Clinically isolated syndrome, oligoclonal bands and multiple sclerosis. Clinical and Experimental Neuroimmunology, 2020, 11, 33-39.	0.5	9
14	JC virus antibodies in Portuguese multiple sclerosis patients: JUSTIFY study results. Journal of the Neurological Sciences, 2019, 406, 116426.	0.3	4
15	Diagnostic Delay of Multiple Sclerosis in a Portuguese Population. Acta Medica Portuguesa, 2019, 32, 289-294.	0.2	22
16	Electrochemical Immunosensor for TNFÎ±-Mediated Inflammatory Disease Screening. ACS Chemical Neuroscience, 2019, 10, 2676-2682.	1.7	19
17	Pregnancy outcomes in Portuguese women with multiple sclerosis: The PREGNIMS study. Multiple Sclerosis and Related Disorders, 2019, 28, 172-176.	0.9	9
18	International consensus on quality standards for brain health-focused care in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1809-1818.	1.4	55

#	Article	IF	Citations
19	Recognizing migraine in patients with multiple sclerosis improves the quality of health care. Arquivos De Neuro-Psiquiatria, 2019, 77, 599-600.	0.3	2
20	Depressive Symptomatology, Presenteeism Productivity, and Quality of Life. Journal of Occupational and Environmental Medicine, 2018, 60, 301-308.	0.9	12
21	Paced Auditory Serial Addition Test (PASAT 3.0â€‰s): Demographically corrected norms for the Portuguese population. Applied Neuropsychology Adult, 2018, 25, 417-423.	0.7	1
22	Verbal Selective Reminding Test (six-trial administration): Regression-based norms for a portuguese version. Applied Neuropsychology Adult, 2018, 25, 523-531.	0.7	2
23	Validation of the brief international cognitive assessment for multiple sclerosis (BICAMS) in the Portuguese population with multiple sclerosis. BMC Neurology, 2018, 18, 172.	0.8	28
24	RecomendaÃ§Ãµes e Consensos do Grupo de Estudos de Esclerose MÃºltipla e da Sociedade Portuguesa de Neurorradiologia sobre ResonÃ¢ncia MagnÃ©tica na Esclerose MÃºltipla na PrÃ¡tica ClÃnica: Parte 1. Acta Medica Portuguesa, 2018, 31, 281.	0.2	0
25	Emerging Biosensing Technologies for Neuroinflammatory and Neurodegenerative Disease Diagnostics. Frontiers in Molecular Neuroscience, 2018, 11, 164.	1.4	25
26	Cerebral autoregulation is preserved in multiple sclerosis patients. Journal of the Neurological Sciences, 2017, 381, 298-304.	0.3	0
27	New insights into the burden and costs of multiple sclerosis in Europe: Results for Portugal. Multiple Sclerosis Journal, 2017, 23, 143-154.	1.4	20
28	Cognitive impairment and magnetic resonance imaging correlates in primary progressive multiple sclerosis. Acta Neurologica Scandinavica, 2017, 136, 109-115.	1.0	18
29	Social support network and quality of life in multiple sclerosis patients. Arquivos De Neuro-Psiquiatria, 2017, 75, 267-271.	0.3	29
30	Autonomic dysfunction in multiple sclerosis is better detected by heart rate variability and is not correlated with central autonomic network damage. Journal of the Neurological Sciences, 2016, 367, 133-137.	0.3	27
31	Prevalence of Autonomic Dysfunction in Patients with Multiple Sclerosis. Acta Medica Portuguesa, 2015, 28, 51-55.	0.2	15
32	BRBN-T validation: adaptation of the Selective Reminding Test and Word List Generation. Arquivos De Neuro-Psiquiatria, 2015, 73, 867-872.	0.3	4
33	Neuromyelitis optica in Portugal (NEMIPORT) â€“ A multicentre study. Clinical Neurology and Neurosurgery, 2015, 134, 79-84.	0.6	5
34	Gluten chorea. Clinical Neurology and Neurosurgery, 2015, 138, 8-9.	0.6	9
35	Multiple Sclerosis Treatment with Natalizumab: Analysis of a Hospital-Based Cohort. Acta Medica Portuguesa, 2014, 27, 437.	0.2	4
36	Relapsingâ€“Remitting Multiple Sclerosis: Patterns of Response to Disease-Modifying Therapies and Associated Factors: A National Survey. Neurology and Therapy, 2014, 3, 89-99.	1.4	9

#	Article	IF	Citations
37	Multiple Sclerosis and Oligodendroglioma: An Exceptional Association. Case Reports in Neurological Medicine, 2014, 2014, 1-5.	0.3	9
38	Exercise therapy and multiple sclerosis: a systematic review. Journal of Neurology, 2014, 261, 1651-1661.	1.8	58
39	Month of birth is not a definite risk factor for multiple sclerosis. Arquivos De Neuro-Psiquiatria, 2014, 72, 397-397.	0.3	2
40	Month of birth and risk of multiple sclerosis in a Portuguese population. Clinical Neurology and Neurosurgery, 2013, 115, 1762-1765.	0.6	12
41	Novel TTC19 mutation in a family with severe psychiatric manifestations and complex III deficiency. Neurogenetics, 2013, 14, 153-160.	0.7	42
42	Social Characteristics and Quality of Life of Portuguese Multiple Sclerosis Patients. Neurology and Therapy, 2013, 2, 43-56.	1.4	8
43	Cognitive Dysfunction in Multiple Sclerosis. Frontiers in Neurology, 2012, 3, 74.	1.1	138
44	Switching and Escalating Therapy in Long-Lasting Multiple Sclerosis: Not Always Necessary. ISRN Neurology, 2012, 2012, 1-5.	1.5	1
45	Physiopathology of symptoms and signs in multiple sclerosis. Arquivos De Neuro-Psiquiatria, 2012, 70, 733-740.	0.3	27
46	The effect of social support on the quality of life of patients with multiple sclerosis. Arquivos De Neuro-Psiquiatria, 2012, 70, 108-113.	0.3	65
47	Disease-modifying drugs for multiple sclerosis must be globally available according to therapeutic guidelines suitable to different regions of the world. Arquivos De Neuro-Psiquiatria, 2012, 70, 761-762.	0.3	0
48	Pain in Portuguese Patients with Multiple Sclerosis. Frontiers in Neurology, 2011, 2, 20.	1.1	10
49	Classical immunomodulatory therapy in multiple sclerosis: how it acts, how it works. Arquivos De Neuro-Psiquiatria, 2011, 69, 536-543.	0.3	29
50	Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders. Current Nanoscience, 2011, 7, 2-20.	0.7	6
51	Acute transverse myelitis: A practical reappraisal. Autoimmunity Reviews, 2009, 9, 128-131.	2.5	45
52	Psychological aspects of multiple sclerosis. Clinical Neurology and Neurosurgery, 2008, 110, 868-877.	0.6	116
53	Devic Disease With Abnormal Brain Magnetic Resonance Image Findings: The First Portuguese Case. Archives of Neurology, 2007, 64, 290.	4.9	10
54	Dendritic right/left asymmetries in the neurons of the human hippocampal formation: a quantitative Golgi study. Arquivos De Neuro-Psiquiatria, 2007, 65, 1105-1113.	0.3	8

#	Article	IF	Citations
55	Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis. Multiple Sclerosis Journal, 2006, 12, 354-356.	1.4	47
56	Multiple Sclerosis Severity Score. Neurology, 2005, 64, 1144-1151.	1.5	836
57	Oligoclonal IgG bands in the cerebrospinal fluid of portuguese patients with multiple sclerosis: negative results indicate benign disease. Arquivos De Neuro-Psiquiatria, 2005, 63, 375-379.	0.3	19
58	Genotypes at the APOE and SCA2 loci do not predict the course of multiple sclerosis in patients of Portuguese origin. Multiple Sclerosis Journal, 2004, 10, 153-157.	1.4	27
59	Dendritic changes in the hippocampal formation of AIDS patients: a quantitative Golgi study. Acta Neuropathologica, 2004, 107, 97-110.	3.9	71
60	Selective loss of hilar neurons and impairment of initial learning in rats after repeated administration of electroconvulsive shock seizures. Experimental Brain Research, 2004, 154, 192-200.	0.7	50
61	A whole genome screen for association with multiple sclerosis in Portuguese patients. Journal of Neuroimmunology, 2003, 143, 112-115.	1.1	13
62	Quality Assurance for Cerebrospinal Fluid Protein Analysis: International Consensus by an Internet-Based Group Discussion. Clinical Chemistry and Laboratory Medicine, 2003, 41, 331-7.	1.4	62
63	AIDS does not alter the total number of neurons in the hippocampal formation but induces cell atrophy: a stereological study. Acta Neuropathologica, 2000, 99, 643-653.	3.9	26
64	Cerebrospinal fluid cytomorphologic findings in 41 intracranial tumors: a retrospective review. Arquivos De Neuro-Psiquiatria, 1995, 53, 218-226.	0.3	7
65	Cytoproteic CSF findings in 33 MS patients: usefulness for diagnosis. Acta Neurologica Scandinavica, 1989, 79, 170-172.	1.0	1
66	Clinical and CSF cyto-proteic findings in 23 patients with CSF eosinophilia. Acta Neurologica Scandinavica, 1986, 73, 279-282.	1.0	9
67	Electrophoretic pattern of cerebrospinal fluid proteins in non-neoplastic infantile hydrocephalus. Acta Neurologica Scandinavica, 1978, 57, 317-328.	1.0	21